文献速递湿疹皮炎与荨麻疹

奈莫利珠单抗治疗慢性肾脏病相关瘙痒的随机对照研究:NIKAIA-1

Randomized controlled study of nemolizumab in patients with chronic kidney disease-associated pruritus: NIKAIA-1.
PubMed 文献 · J Am Acad Dermatol · 2026-09-01

NIKAIA-1 是一项为期12周的随机、安慰剂对照研究,纳入258例血液透析合并慢性肾脏病相关瘙痒患者,评估奈莫利珠单抗30 mg或60 mg每4周一次的安全性与疗效。

要点

  • 主要终点未达到:第12周瘙痒改善≥4分比例60 mg组47.7%、30 mg组38.5%,安慰剂组32.4%。
  • 起效迅速:第4周≥4分改善率24.3%~26.6%,安慰剂组7.4%。

核心结论

  • 虽然主要终点未达到,但奈莫利珠单抗在12周内显示出良好的安全性,并有减轻瘙痒和改善瘙痒相关生活质量的信号。

研究设计与样本

  • 12周随机、安慰剂对照研究,纳入258例血液透析合并慢性肾脏病相关瘙痒患者,奈莫利珠单抗30 mg或60 mg每4周一次。

主要发现

  • 第4周最严重瘙痒数字评定量表改善≥4分的患者比例:奈莫利珠单抗组24.3%~26.6%,安慰剂组7.4%。
  • 与研究药物相关的不良事件在各组间相当。

临床怎么用

  • 对于血液透析合并慢性肾脏病相关瘙痒患者,奈莫利珠单抗可能快速减轻瘙痒并改善生活质量,但主要终点未达到,需结合个体情况评估使用。

局限性

  • 样本量相对较小,随访时间仅12周,需更长期研究评估长期治疗的安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Managing pruritus in hemodialysis patients is challenging. Nemolizumab, a monoclonal antibody targeting IL-31, has demonstrated efficacy in atopic dermatitis and prurigo nodularis with fast reduction of pruritus. OBJECTIVE: To evaluate nemolizumab safety and efficacy for treatment of chronic kidney disease-associated pruritus. METHODS: This was a 12-week randomized, placebo-controlled study of nemolizumab (30 mg or 60 mg) Q4W in 258 hemodialysis patients with chronic kidney disease-associated pruritus. Endpoints assessed safety, and efficacy on pruritus, sleep disturbances, and quality of life. RESULTS: The primary endpoint (proportion of patients with ≥4-point-improvement in Worst Itch-Numerical Rating Scale at week 12) was not met for either nemolizumab dose (60 mg: 47.7% [P = .0686], 30 mg: 38.5% [P = .37]) versus placebo (32.4%). Patient-reported itch-related quality of life improved on Skindex-10 in the 60 mg group vs placebo (nominal P < .01). Onset of action on itch was rapid. At week 4, ≥4-point-improvement in Worst Itch-Numerical Rating Scale was achieved in 24.3% to 26.6% (nemolizumab) compared with 7.4% (placebo). Adverse events related to study drug were comparable among groups. LIMITATIONS: The primary limitation was the relatively small sample size and duration of follow-up (12 weeks); longer studies would be required to evaluate safety and efficacy of long-term treatment. CONCLUSIONS: Although the primary endpoint was not met, the trial demonstrated a favorable safety profile and signals of reduced pruritus and improved itch-related quality of life in patients with chronic kidney disease-associated pruritus over 12 weeks.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Mathur VS, Fishbane S, Ständer S, et al. Randomized controlled study of nemolizumab in patients with chronic kidney disease-associated pruritus: NIKAIA-1. J Am Acad Dermatol. 2026. PMID: 42680109. doi:10.1016/j.jaad.2026.08.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。